GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

002424

CNE100000PY3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
6.46 ^CNY	+1.25%		-0.77%	-20.35%

Apr. 29	Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	CI

Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.

April 02, 2024 at 12:00 pm EDT

From February 2, 2024 to March 31, 2024, the company has repurchased 11,668,812 shares, representing 0.84% for CNY 84.62 million. With this, the company has completed the repurchase of 11,668,812 shares, representing 0.84% for CNY 84.62 million under the buyback announced on February 3, 2024.

Latest news about Guizhou Bailing Group Pharmaceutical Co., Ltd.

Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	Apr. 02	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Feb. 02	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Feb. 01	CI
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug	Dec. 28	MT
China steel association says EU carbon tax a new trade barrier, calls for more talks	Nov. 03	RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
China’s Steel Consumption Falls 1.5% in January-September Period	23-10-24	MT
China steel supply needs adjusting, industry official says	23-10-24	RE
EU to launch first phase of world-first CO2 border tax	23-09-13	RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-07-10	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 9, 2023 has closed with 12,096,900 shares, representing 0.87% for CNY 100.01 million.	23-07-06	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-07-04	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Announces Management Appointments	23-06-06	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-04-03	CI
Zhejiang Futures Co., Ltd completed the acquisition of 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei.	23-03-30	CI
Zhejiang Futures Co., Ltd agreed to acquire a 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei for approximately CNY 210 million.	23-02-28	CI
GZ Bailing Buys Ownership of Traditional Chinese Drug for 20 Million Yuan; Shares Rose 3%	23-01-16	MT
Guizhou Bailing Group Pharma to Repurchase Up to 200 Million Yuan Shares	23-01-09	MT
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	23-01-09	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-01-08	CI
Zhang Shanlin completed the acquisition of 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Yong for approximately ¥500 million.	22-12-20	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

Duration

Period

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

More charts

Company Profile

GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Guizhou Bailing Group Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.46

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.	-20.35%	1.24B
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.16B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.6B

Alternative Medicine

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Equities

002424

CNE100000PY3

Pharmaceuticals

Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.

Latest news about Guizhou Bailing Group Pharmaceutical Co., Ltd.

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Guizhou Bailing Group Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Alternative Medicine